COVID-19 in China, Italy and the United States of America: a short review
DOI:
https://doi.org/10.11606/issn.1679-9836.v100i2p162-170Keywords:
Coronavirus Infections, Epidemiology, Pandemics, Signs and symptomsAbstract
In December 2019, a novel coronavirus was discovered and associated with a cluster of pneumonia of unknown cause in China. SARS-CoV-2 rapidly spread and is now characterized as a pandemic. The objective of this study is to discuss COVID-19 general features, including epidemiology, transmission, control measures, virology, diagnosis, clinical characteristics and radiological and laboratory results. In this context, literature was assessed to compare the three most affected countries in Asia, Europe and Americas on March 31, 2020. The main form of transmission is human-to-human by respiratory secretions, and studies indicated substantial involvement of asymptomatic patients in this process. COVID-19 patients are predominantly men and may present multiple symptoms, especially fever and cough. Arterial hypertension and diabetes mellitus were the most common comorbidities. Worse outcomes are associated with increased age, comorbidities, and complications. Abnormalities in computed tomography of the chest are frequent, with pulmonary ground-glass opacity and bilateral patchy shadowing as the most common patterns, but a significant percentage of patients do not present any findings at time of admission. Laboratory results often present lymphocytopenia, increased neutrophils and platelet counts, erythrocyte sedimentation rate, lactate dehydrogenase, C-reactive protein, ferritin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine, creatine phosphokinase, myoglobin, glucose and cytokines. Although radiological findings and laboratory results presented similarities in China, Italy and USA, case-fatality rates can be conflicting suggesting, therefore, the need for studies according to each region.
Downloads
References
Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med Res. 2020;7(1):1-10. doi: 10.1186/s40779-020-00240-0.
Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020;94:44-8. doi: 10.1016/j.ijid.2020.03.004.
Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298. doi: 10.3389/fmicb.2020.00298.
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: 10.1038/s41368-020-0074-x.
World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 71. Genève; 2020 [cited 2020 April 01]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_8.
World Health Organization. COVID-19 strategic preparedness and response plan operational planning guidelines to support country preparedness and response. Genève; 2020 [cited 2020 April 23]. Available from: https://www.who.int/docs/default-source/coronaviruse/covid-19-sprp-unct-guidelines.pdf.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 51. Genève; 2020 [cited 2020 April 27]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.
World Health Organization. WHO COVID-19 Dashboard. Genève; 2020 [cited 2020 May 05]. Covid19.who.int. 2020. Available from: https://covid19.who.int.
Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): a Chinese perspective. J Med Virol. 2020;92(6):639-44. doi: 10.1002/jmv.25749.
Gandhi R, Lynch J, del Rio C. Mild or moderate Covid-19. New Engl J Med. 2020;383(18):1757-66. doi: 10.1056/NEJMcp2009249.
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-4. doi: 10.1001/jama.2020.3786.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.
Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry B. Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China. J Med Virol. 2020;92:1759-60. doi: 10.1002/jmv.25860.
Arons M, Hatfield K, Reddy S, Kimball A, James A, Jacobs J, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. New Engl Med. 2020;382:2081-90. doi: 10.1056/NEJMoa2008457.
Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. New Engl J Med. 2020;382(12):1177-9. doi: 10.1056/NEJMc2001737.
Wei W, Li Z, Chiew C, Yong S, Toh M, Lee V. Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:411-5. doi: 10.15585/mmwr.mm6914e1.
Tong Z, Tang A, Li K, Li P, Wang H, Yi J, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5):1052-4. doi: 10.3201/eid2605.200198.
Qian G, Yang N, Ma A, Wang L, Li G, Chen X, et al. COVID-19 transmission within a family cluster by presymptomatic carriers in China. Clin Infect Dis. 2020;94:133-8. doi: 10.1016/j.ijid.2020.03.042.
World Health Organization. COVID‑19 strategy update - 14 April 2020. Genève; 2020 [cited 2020 April 23]. Available from: https://www.who.int/publications-detail/covid-19-strategy-update---14-april-2020.
Wang C, Pan R, Wan X, Tan Y, Xu L, Ho C, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17(5):1729. doi: 10.3390/ijerph17051729.
Lima C, Carvalho P, Lima I, Nunes J, Saraiva J, de Souza R, et al. The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). Psychiatr Res. 2020;287:112915. doi: 10.1016/j.psychres.2020.112915.
Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: a review. Int J Surg. 2020;78:185-93. doi: 10.1016/j.ijsu.2020.04.018.
Page K, Venkataramani M, Beyrer C, Polk S. Undocumented U.S. Immigrants and Covid-19. New Engl J Med. 2020; 382(21):e62. doi: 10.1056/NEJMp2005953.
Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol. 2020;92(5):491-4. doi: 10.1002/jmv.25709.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi: 10.1016/S0140-6736(20)30251-8.
Shereen M, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8. doi: 10.1016/j.jare.2020.03.005.
Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948. doi: 10.1016/j.ijantimicag.2020.105948.
de Wit E, van Doremalen N, Falzarano D, Munster V. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016;14(8):523-34. doi: 10.1038/nrmicro.2016.81.
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-92. doi: 10.1007/s11684-020-0754-0.
World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. Genève; 2020 [cited 2020 April 23]. Available from: https://apps.who.int/iris/handle/10665/331506.
World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. Genève; 2020 [cited 2020 April 23]. Available from: https://apps.who.int/iris/handle/10665/331329.
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). 2020 [cited 2020 April 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.
Sharfstein J, Becker S, Mello M. Diagnostic Testing for the Novel Coronavirus. JAMA. 2020;323(15):1437. doi: 10.1001/jama.2020.3864.
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-6. doi: 10.1001/jama.2020.4683.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. doi: 10.1016/S2213-2600(20)30079-5.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi: 10.1001/jama.2020.5394.
Bhatraju P, Ghassemieh B, Nichols M, Kim R, Jerome K, Nalla A, et al. Covid-19 in critically Ill patients in the Seattle Region — case series. New Engl J Med. 2020;382:2012-22. doi: 10.1056/NEJMoa2004500.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612. doi: 10.1001/jama.2020.4326.
Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Weekly Rep. 2020;69(12):343-6. doi: 10.15585/mmwr.mm6912e2.
Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Weekly Rep. 2020;69(13):382-6. doi: 10.15585/mmwr.mm6913e2.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7. doi: 10.26355/eurrev_202004_21046.
Sommer P, Lukovic E, Fagley E, Long D, Sobol J, Heller K, et al. Initial clinical impressions of the critical care of COVID-19 patients in Seattle, New York City, and Chicago. Anesth Analg. 2020;131(1):55-60. doi: 10.1213/ANE.0000000000004830.
Porcheddu R, et al. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Countries. 2020;14(02):125-8. doi: 10.3855/jidc.12600.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Amanda Ribeiro Rangel, Luísa Macambira Noronha, Gabriel Cavalcante Lima Chagas, Gdayllon Cavalcante Meneses, Geraldo Bezerra da Silva Júnior, Roberto da Justa Pires Neto, Elizabeth De Francesco Daher
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
